Canabidiol (CBD)

Estudos sobre o Canabidiol (CBD):

 

  

 

Referências:

1. Andre CM, Hausman JF, Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. Front Plant Sci. 2016;7(FEB2016):1-17. doi:10.3389/fpls.2016.00019

 

2. Barrales-Cureño HJ, López-Valdez LG, Reyes C, et al. Chemical characteristics, therapeutic uses, and legal aspects of the cannabinoids of Cannabis sativa: A review. Brazilian Arch Biol Technol. 2020;63:1-14. doi:10.1590/1678-4324-2020180222

 

3. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3). doi:10.3390/ijms19030833

 

4. Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238(1):9-28. doi:10.1007/s00213-020-05712-8

 

5. White CM. A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019;59(7):923-934. doi:10.1002/jcph.1387

 

6. Joshi N, Onaivi ES. Endocannabinoid System Components: Overview and Tissue Distribution. Adv Exp Med Biol. 2019;1162:1-12. doi:10.1007/978-3-030-21737-2_1

 

7. An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting cannabinoid receptors: Current status and prospects of natural products. Int J Mol Sci. 2020;21(14):1-33. doi:10.3390/ijms21145064

 

8. de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect. 2020;8(6):1-10. doi:10.1002/prp2.682

 

9. Sulcova A. Pharmacodynamics of cannabinoids. Arch Pharm Pharm Sci. 2019;3(1):011-018. doi:10.29328/journal.apps.1001013

 

10. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-4805. doi:10.1111/bph.13250

 

11. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105(7):2699-2704. doi:10.1073/pnas.0711278105

 

12. Martínez-Aguirre C, Carmona-Cruz F, Velasco AL, et al. Cannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for Treating Temporal Lobe Epilepsy. Front Behav Neurosci. 2020;14(December):1-8. doi:10.3389/fnbeh.2020.611278

 

13. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037-1043. doi:10.1007/s11064-005-6978-1

 

14. Pumroy RA, Samanta A, Liu Y, et al. Molecular mechanism of TRPV2 channel modulation by cannabidiol. Elife. 2019;8:1-17. doi:10.7554/elife.48792

 

15. de Petrocellis L, Orlando P, Moriello AS, et al. Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. 2012;204(2):255-266. doi:10.1111/j.1748-1716.2011.02338.x

 

16. Murillo-Rodriguez E, Pandi-Perumal SR, Montiieditors JM. Cannabinoids and Neuropsychiatric Disorders.; 1264. http://www.springer.com/series/5584

 

17. Samanta D. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatr Neurol. 2019;96:24-29. doi:10.1016/j.pediatrneurol.2019.03.014

 

18. Szaflarski JP, Bebin EM, Cutter G, et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018;87:131-136. doi:10.1016/j.yebeh.2018.07.020

 

19. Chen JW, Borgelt LM, Blackmer AB. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. Ann Pharmacother. 2019;53(6):603-611. doi:10.1177/1060028018822124

 

20. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. doi:10.1016/S0140-6736(18)30136-3

 

21. Franco V, Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019;79(13):1435-1454. doi:10.1007/s40265-019-01171-4

 

22. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/nejmoa1611618

 

23. Miller I, Scheffer IE, Gunning B, et al. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-621. doi:10.1001/jamaneurol.2020.0073

 

24. Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N Engl J Med. 2018;378(20):1888-1897. doi:10.1056/nejmoa1714631

 

25. Reddy DS. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Clin Pharmacol Ther. 2017;101(2):182-184. doi:10.1002/cpt.441

 

26. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131. doi:10.1111/j.1468-1331.2010.03328.x

 

27. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451-459. doi:10.1179/016164109X12590518685660

 

28. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417-424. doi:10.1191/1352458504ms1048oa

 

29. Rog DJ, Nurmikko TJ, Young CA. Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079. doi:10.1016/j.clinthera.2007.09.013

 

30. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290-296. doi:10.1111/j.1468-1331.2006.01639.x

 

31. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819. doi:10.1212/01. wnl.0000176753.45410.8b

 

32. Markovà J, Essner U, Akmaz B, et al. Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebocontrolled randomised clinical trial. Int J Neurosci. 2019;129(2):119-128. doi:10.1080/00207454.2018.1481066

 

33. Leocani L, Nuara A, Houdayer E, et al. Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol. 2015;262(11):2520-2527. doi:10.1007/ s00415-015-7878-1

 

34. Serpell MG, Notcutt W, Collin C. Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013;260(1):285-295. doi:10.1007/s00415-012-6634-z

 

35. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210-220. doi:10.1016/j.pain.2007.08.028

 

36. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438-449. doi:10.1016/j.jpain.2012.01.003

 

37. Lichtman AH, Lux EA, McQuade R, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage. 2018;55(2):179-188.e1. doi:10.1016/j.jpainsymman.2017.09.001

 

38. Berger AA, Keefe J, Winnick A, et al. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. Best Pract Res Clin Anaesthesiol. 2020;34(3):617-631. doi:10.1016/j.bpa.2020.08.010

 

39. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Curr Pharm Biotechnol. 2019;21(5):390- 402. doi:10.2174/1389201020666191202111534

 

40. Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;2015(11). doi:10.1002/14651858.CD009464.pub2

 

41. Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019;25(4):392-397. doi:10.1089/ acm.2018.0437

 

42. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6

 

43. Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27(8):795-808. doi:10.1016/j.euroneuro.2017.05.005

 

44. Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol for the treatment of psychosis in Parkinsons disease. J Psychopharmacol. 2009;23(8):979-983. doi:10.1177/0269881108096519

 

45. de Faria SM, de Morais Fabrício D, Tumas V, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol. 2020;34(2):189-196. doi:10.1177/0269881119895536

 

46. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40(3):701-708. doi:10.1016/0091-3057(91)90386-G

 

47. Baswan SM, Klosner AE, Glynn K, et al. Therapeutic potential of cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig Dermatol. 2020;13:927-942. doi:10.2147/CCID.
S286411

 

48. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020;12(3):129-141. doi:10.14740/ jocmr4090

 

49. Perucca E, Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs. 2020;34(8):795-800. doi:10.1007/ s40263-020-00741-5

 

50. Mozaffari K, Willette S, Lucker BF, Kovar SE, Holguin FO, Guzman I. The effects of food on cannabidiol bioaccessibility. Molecules. 2021;26(12). doi:10.3390/molecules26123573

 

51. Ferreira A de O, Brandão MAF, Polonini HC. Guia Prático Da Farmácia Magistral. 5a.; 2018.

 

52. Meeting F. Cannabidiol (CBD) Critical Review Report. World Heal Organ. Published online 2018. https://www.who.int/medicines/access/controlled-substances/WHOCBDReportMay2018-2.pdf

 

53. Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Alexandre S. Crippa J. Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Curr Drug Saf. 2011;6(4):237- 249. doi:10.2174/157488611798280924

 

54. Brown J, Winterstein A. Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019;8(7):989. doi:10.3390/jcm8070989

 

55. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5-6):165-170. doi:10.1016/j.lfs.2011.05.018